Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit Verma

Showing results (441-450 of 459) with videos related to

Pageof 46
Sort By:
Elife|August 30, 2022
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutationsGaurav S Choudhary, Andrea Pellagatti, Bogos Agianian, et al.
Leukemia|February 17, 2026
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemiaSamarpana Chakraborty, Claudia Morganti, Kimberly Zaldana, et al.
Cell Reports|July 28, 2021
Methylation of dual-specificity phosphatase 4 controls cell differentiationHairui Su, Ming Jiang, Chamara Senevirathne, et al.
Cancer Research|June 12, 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLohith Bachegowda, Kerry Morrone, Shannon L Winski, et al.
Blood|August 15, 2018
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapiesUrvi A Shah, Elaine Y Chung, Orsi Giricz, et al.
The Journal of Clinical Investigation|September 26, 2018
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cellsAditi Shastri, Gaurav Choudhary, Margarida Teixeira, et al.
Nature Communications|May 13, 2026
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesisSrinivas Aluri, Kimo Bachiashvili, Anjali Budhathoki, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Blood|November 22, 2019
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasmsLanzhu Yue, Vasundhara Sharma, Nathan P Horvat, et al.
Pageof 46

Showing results (441-450 of 459) with videos related to

Sort By:
Pageof 46
Elife|August 30, 2022
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutationsGaurav S Choudhary, Andrea Pellagatti, Bogos Agianian, et al.
Leukemia|February 17, 2026
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemiaSamarpana Chakraborty, Claudia Morganti, Kimberly Zaldana, et al.
Cell Reports|July 28, 2021
Methylation of dual-specificity phosphatase 4 controls cell differentiationHairui Su, Ming Jiang, Chamara Senevirathne, et al.
Cancer Research|June 12, 2016
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLohith Bachegowda, Kerry Morrone, Shannon L Winski, et al.
Blood|August 15, 2018
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapiesUrvi A Shah, Elaine Y Chung, Orsi Giricz, et al.
The Journal of Clinical Investigation|September 26, 2018
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cellsAditi Shastri, Gaurav Choudhary, Margarida Teixeira, et al.
Nature Communications|May 13, 2026
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesisSrinivas Aluri, Kimo Bachiashvili, Anjali Budhathoki, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesAdila Izgutdina, Tasfia Rashid, William C Temple, et al.
Blood|November 22, 2019
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasmsLanzhu Yue, Vasundhara Sharma, Nathan P Horvat, et al.
Pageof 46